Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a Phase I clinical study for its ABSK061, an oral highly selective FGFR2/3 inhibitor, in solid tumors. The molecule is described as the first of its kind globally to reach the clinical stages.
Study Details
The study, being conducted concurrently in China and the US, is designed to assess the safety, tolerability, and pharmacokinetics of ABSK061 in advanced solid tumors. It will also determine the recommended Phase II dosage and evaluate the preliminary clinical efficacy of the drug when administered orally.
Drug Profile
ABSK061 is a second-generation FGFR inhibitor with reduced inhibition of FGFR1 but high activity against FGFR2/3. This profile has the potential to offer an improved safety window and enhanced efficacy compared to other pan-FGFR inhibitors. Beyond treating tumors, the drug also shows promise in addressing conditions like achondroplasia.-Fineline Info & Tech
